Inhibition of urease-mediated ammonia production by 2-octynohydroxamic acid in hepatic encephalopathy
Diana Evstafeva, Filip Ilievski, Yinyin Bao, Zhi Luo, Boris Abramovic, Sunghyun Kang, Christian Steuer, Elita Montanari, Tommaso Casalini, Dunja Simičić, Dario Sessa, Stefanita-Octavian Mitrea, Katarzyna Pierzchała, Cristina Cudalbu, Chelsie E. Armbruster, Jean‐Christophe Leroux
Abstract
Hepatic encephalopathy is a neuropsychiatric complication of liver disease which is partly associated with elevated ammonemia. Urea hydrolysis by urease-producing bacteria in the colon is often mentioned as one of the main routes of ammonia production in the body, yet research on treatments targeting bacterial ureases in hepatic encephalopathy is limited. Herein we report a hydroxamate-based urease inhibitor, 2-octynohydroxamic acid, exhibiting improved in vitro potency compared to hydroxamic acids that were previously investigated for hepatic encephalopathy. 2-octynohydroxamic acid shows low cytotoxic and mutagenic potential within a micromolar concentration range as well as reduces ammonemia in rodent models of liver disease. Furthermore, 2-octynohydroxamic acid treatment decreases cerebellar glutamine, a product of ammonia metabolism, in male bile duct ligated rats. A prototype colonic formulation enables reduced systemic exposure to 2-octynohydroxamic acid in male dogs. Overall, this work suggests that urease inhibitors delivered to the colon by means of colonic formulations represent a prospective approach for the treatment of hepatic encephalopathy.